Re:Medical-evidence giant Cochrane battles funding cuts and ...
by ggm on Monday September 04, 2023 @05:10PM
(#37385106)
As I've said above it was subject to pretty hefty critique and I've never seen a robust defence. They meta combined papers which were not well grounded and it was unlike its RCT normal approach.
[ Parent
| on HN ]
There are no comments on this comment yet.